Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link?

Eva Karamitopoulou, Eva Karamitopoulou

Abstract

Pancreatic ductal adenocarcinoma (PDAC) ranks as the fourth commonest cause of cancer death while its incidence is increasing worldwide. For all stages, survival at 5 years is<5%. The lethal nature of pancreatic cancer is attributed to its high metastatic potential to the lymphatic system and distant organs. Lack of effective therapeutic options contributes to the high mortality rates of PDAC. Recent evidence suggests that epithelial-mesenchymal transition (EMT) plays an important role to the disease progression and development of drug resistance in PDAC. Tumor budding is thought to reflect the process of EMT which allows neoplastic epithelial cells to acquire a mesenchymal phenotype thus increasing their capacity for migration and invasion and help them become resistant to apoptotic signals. In a recent study by our own group the presence and prognostic significance of tumor budding in PDAC were investigated and an association between high-grade budding and aggressive clinicopathological features of the tumors as well as worse outcome of the patients was found. The identification of EMT phenotypic targets may help identifying new molecules so that future therapeutic strategies directed specifically against them could potentially have an impact on drug resistance and invasiveness and hence improve the prognosis of PDAC patients. The aim of this short review is to present an insight on the morphological and molecular aspects of EMT and on the factors that are involved in the induction of EMT in PDAC.

Keywords: biomarker; epithelial-mesenchymal transition; pancreatic cancer; prognosis; tumor budding.

Figures

Figure 1
Figure 1
Schematic representation of the EMT process in pancreatic cancer depicting the hypothetical link to tumor budding.

References

    1. Hidalgo M. Pancreatic cancer. N Engl J Med (2010) 362:1605–1710.1056/NEJMra0901557
    1. Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol (2005) 70:65–7210.1101/sqb.2005.70.040
    1. Fernandez-del-Castillo C, Jimenez RE, Steer ML. Surgery in the treatment of exocrine pancreas and prognosis. In: Tanabe KK, editor (2013). Available from:
    1. Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett (2012). Available from: ,
    1. Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med (2007) 7:504–2110.2174/156652407781387082
    1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119:1420–810.1172/JCI39104
    1. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139:871–9010.1016/j.cell.2009.11.007
    1. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 102:340–5110.1093/jnci/djp535
    1. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S. Epithelial–mesenchymal transition in cancer development and its clinical significance. Cancer Sci (2010) 101(2):293–910.1111/j.1349-7006.2009.01419.x
    1. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest (2009) 119:1417–910.1172/JCI39675
    1. Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2012) 173:105–1210.1016/j.jss.2011.09.020
    1. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 172:973–8110.1083/jcb.200601018
    1. Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res (2007) 13:4769–7610.1158/1078-0432.CCR-06-2926
    1. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 69:5820–810.1158/0008-5472.CAN-08-2819
    1. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther (2007) 6:532–4110.1158/1535-7163.MCT-06-0462
    1. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett (2010) 295:214–2810.1016/j.canlet.2010.03.003
    1. Prall F. Tumour budding in colorectal carcinoma. Histopathology (2007) 50:151–6210.1111/j.1365-2559.2006.02551.x
    1. Brown M, Sillah K, Griffiths EA, Swindell R, West CM, Page RD, et al. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology (2010) 56:893–910.1111/j.1365-2559.2010.03559.x
    1. Koike M, Kodera Y, Itoh Y, Nakayama G, Fujiwara M, Hamajima N, et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Ann Surg Oncol (2008) 15:1977–8210.1245/s10434-008-9901-6
    1. Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer (2009) 115:3324–3410.1002/cncr.24390
    1. Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus (2004) 17:333–710.1111/j.1442-2050.2004.00436.x
    1. Ohike N, Coban I, Kim GE, Basturk O, Tajiri T, Krasinskas A, et al. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol (2010) 34:1417–2410.1097/PAS.0b013e3181f0b05a
    1. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1:651–61
    1. Muto T, Mochizuki H, Masaki T. editors. Tumor Budding in Colorectal Cancer: Recent Progress in Colorectal Cancer Research (Horizons in Cancer Research). (Vol. 8). Tokyo: Nova; (2006).
    1. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev (2009) 28:151–6610.1007/s10555-008-9179-y
    1. Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol (2013) 26:295–30110.1038/modpathol.2012.155
    1. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology (2005) 52: 1432–5
    1. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg (2004) 91:327–3310.1002/bjs.4429
    1. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology (2002) 40:127–3210.1046/j.1365-2559.2002.01324.x
    1. Wang LM, Kevans D, Mulcahy H, O’Sullivan J, Fennelly D, Hyland J, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol (2009) 33:134–4110.1097/PAS.0b013e318184cd55
    1. Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Patsouris E, Gennatas K, et al. Tumor budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer (2013) 49:1032–910.1016/j.ejca.2012.10.022
    1. Calin GA, Croce CM. Micro RNA signatures in human cancers. Nat Rev Cancer (2006) 6:857–6610.1038/nrc1997
    1. McShane L, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Eur J Cancer (2005) 41:1690–610.1016/j.ejca.2005.03.032
    1. Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Gen Dev (2005) 15:200–510.1016/j.gde.2005.01.002
    1. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 8:843–5210.4161/cc.8.6.7907
    1. Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, et al. MicroRNA10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 17:5812–2110.1158/1078-0432.CCR-11-0695
    1. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 10:593–60110.1038/ncb1722
    1. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 9:582–910.1038/embor.2008.74
    1. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT- activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 11:1487–9510.1038/ncb1998
    1. Panarelli NC, Chen YT, Zhou XK, Kitabayashi N, Yantiss RK. MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas (2012) 41:685–9010.1097/MPA.0b013e318243a905
    1. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg (2008) 12:2171–610.1007/s11605-008-0584-x
    1. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer (2010) 9:169.10.1186/1476-4598-9-169
    1. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res (2007) 67:1030–710.1158/0008-5472.CAN-06-2030
    1. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol (2008) 26:2806–1210.1200/JCO
    1. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer (2009) 125:2323–3110.1002/ijc.24573
    1. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 1:313–2310.1016/j.stem.2007.06.002
    1. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 69:6704–1210.1158/0008-5472.CAN-09-1298
    1. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 12:4147–5310.1158/1078-0432.CCR-06-0038
    1. Shah AN, Summy JM, Zhang J, Park S, Parikh N, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 14:3629–3710.1245/s10434-007-9583-5
    1. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 138:592–60310.1016/j.cell.2009.07.011
    1. Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol (2005) 23:1228–3610.1200/JCO.2005.06.050

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren